Concomitant treatment with the Chk1/2 inhibitor significantly increased the ability of irinotecan to inhibit in vitro cell proliferation of both KRAS wild type and mutant CRC-SC lines (Figure 5A). This evidence concerns the gene KRAS and colorectal carcinoma.